Khang & Khang LLP announces that it is investigating claims of potential
misrepresentations by MannKind Corp. (“MannKind” or the
“Company”) (NASDAQ: MNKD).
The investigation focuses on whether the Company and its officers
violated securities laws by issuing misleading information to investors.
If you purchased shares of MannKind during the Class Period, please
contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman
Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by
email at joon@khanglaw.com.
There has been no class certification in this case. Until certification
occurs, you are not represented by an attorney. You may choose to take
no action and remain a passive class member.
The investigation concerns whether the Company violated Sections 10(b)
and 20(a) of the Securities Exchange Act of 1934. Specifically, the
investigation will focus on the Company’s January 5, 2016 announcement
that French pharmaceutical giant Sanofi will no longer market and
distribute Afrezza.
If you wish to learn more about this lawsuit, or if you have any
questions concerning this notice or your rights, please contact Joon M.
Khang, a prominent litigator for almost two decades, by telephone: (949)
419-3834, or by email at joon@khanglaw.com.
This press release may constitute Attorney Advertising in some
jurisdictions.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160106006471/en/
Copyright Business Wire 2016